Meet four hypothetical patients with R/R follicular lymphoma and consider how they might benefit from TAZVERIK®
These hypothetical case studies are presented only as examples. They are not intended to instruct any healthcare provider in the treatment of any illness; nor are they meant to substitute for medical training or to be relied upon in treating any individual patient. The healthcare provider reading this case study should use his or her own knowledge, education, training, and judgment when treating patients. Information presented does not encompass all considerations for TAZVERIK® eligibility. These hypothetical profiles are examples of the range of patient characteristics that may be considered to inform treatment decision. Patient experience may vary.
All patient photos are actor portrayals.
Meet John
Hypothetical patient.
- 63-year-old patient with EZH2 MT status
- Requires third-line treatment
Current presentation
- Bloodwork shows elevated WBC and increased cervical lymphadenopathy
Clinical history
- Diagnosed with FL at age 53
- 1 year after diagnosis, B symptoms (soaking night sweats, fatigue) necessitated treatment
- First-line treatment: 6 cycles of BR followed by R maintenance for 2 years
- –After 4 years of follow-up, a recurrence of multiple B symptoms indicated R/R disease
- Second-line treatment: 6 cycles of R-CHOP followed by R maintenance
- –18 months after completing therapy, John developed recurrent fevers. Imaging has revealed disease progression
Treatment considerations
- High cholesterol, controlled with medication
- No other comorbidities; overall physically fit
- Has a history of infusion-site reactions
Would you consider Tazverik
as a treatment option for
this patient?
TAZVERIK® efficacy and safety were evaluated in 2 open-label, independent, single-arm cohorts
(EZH2 WT [n=54] and MT [n=45]) of a multicenter study in patients with histologically confirmed follicular
lymphoma after at least 2 prior systemic therapies. The primary efficacy endpoint was the overall
response rate (ORR) and a secondary efficacy endpoint was duration of response (DOR).1,2
Primary endpoint:
69% ORR*
in MT FL (29/42)
(95% CI: 53%-82%)1,3
Secondary endpoint:
10.9 months median DOR
in MT FL (range: 0.0-≥22.1 months;
n=29/42; 95% CI: 7.2-NE)1,3
Secondary endpoint: 10.9 months median DOR
in MT FL (range: 0.0-≥22.1 months; n=29/42;
95% CI: 7.2-NE)1,3
Median time to overall response for
patients with EZH2 MT FL was
3.7 months (range: 1.6 to 10.9).1
Median time to overall response for patients with EZH2 MT FL was 3.7 months (range: 1.6 to 10.9).1
Oral, twice-daily dosing1
The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%)1
*According to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by Independent Radiology Committee.
BR=bendamustine + rituximab; CI=confidence interval; EZH2=enhancer of zeste homolog 2; FL=follicular lymphoma; MT=mutant type; NE=not evaluable; R=rituximab; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone; R/R=relapsed or refractory; WBC=white blood cells; WT=wild type.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration
of response. Continued approval for these indications may be contingent upon verification and
description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Secondary Malignancies: TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies.
- Embryo-Fetal Toxicity: TAZVERIK can cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception.
The most common (≥20%) adverse reactions in patients with follicular lymphoma are fatigue, upper
respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.
Please see additional Important Safety Information below and full Prescribing Information.
Meet Mary
Hypothetical patient.
- 64-year-old patient with EZH2 WT status
- Comorbidities include type 2 diabetes hypertension, and obesity
Current presentation
- Bloodwork shows elevated WBC and increased cervical lymphadenopathy
- PET scan and laboratory analysis reveal disease progression
Clinical history
- Diagnosed with FL at age 54
- First-line treatment: 6 cycles of BR followed by R maintenance
- –After 4 years, Mary began to suffer from night sweats and fatigue. Analyses showed anemia, elevated LDH, recurrent lymphadenopathy, and disease recurrence
- Second-line treatment (age 60): 5 cycles of R2, then lenalidomide for a total of 12 months
- –~3 years after completing lenalidomide, progression of FL has been confirmed by imaging
Treatment considerations
- Concerned about side effects given her comorbidities
- Also concerned about whether Medicare will cover her treatment
Would you consider Tazverik
as a treatment option for
this patient?
TAZVERIK® efficacy and safety were evaluated in 2 open-label, independent, single-arm cohorts
(EZH2 WT [n=54] and MT [n=45]) of a multicenter study in patients with histologically confirmed follicular
lymphoma after at least 2 prior systemic therapies. The primary efficacy endpoint was the overall
response rate (ORR) and a secondary efficacy endpoint was duration of response (DOR).1,2
Primary endpoint:
34% ORR*
in WT FL (18/53)
(95% CI: 22%-48%)1,3
Secondary endpoint:
13.0 months median DOR
in WT FL (range: 1.0-≥22.5 months;
n=18/53; 95% CI: 5.6-NE)1,3
Secondary endpoint: 13.0 months median DOR
in WT FL (range: 1.0-≥22.5 months; n=18/53;
95% CI: 5.6-NE)1,3
Median time to overall response for
patients with EZH2 WT FL was
3.9 months (range: 1.6 to 16.3).1
Median time to overall response for patients with EZH2 WT FL was 3.9 months (range: 1.6 to 16.3).1
8% of patients permanently
discontinued treatment due
to an adverse reaction1
8% of patients permanently discontinued treatment due to an adverse reaction1
The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%)1
*According to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by Independent Radiology Committee.
BR=bendamustine + rituximab; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; EZH2=enhancer of zeste homolog 2; FL=follicular lymphoma; MT=mutant type; LDH=lactate dehydrogenase; NE=not evaluable; PET=positron emission tomography; R=rituximab; R2=lenalidomide + rituximab; R/R=relapsed or refractory; WBC=white blood cells; WT=wild type.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration
of response. Continued approval for these indications may be contingent upon verification and
description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Secondary Malignancies: TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies.
- Embryo-Fetal Toxicity: TAZVERIK can cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception.
The most common (≥20%) adverse reactions in patients with follicular lymphoma are fatigue, upper
respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.
Please see additional Important Safety Information below and full Prescribing Information.
Meet Camilla
Hypothetical patient.
- 61-year-old patient with unknown EZH2 status
- Requires third-line treatment to manage a relapse with mild symptoms
Current presentation
- Mild symptoms and PET scans show slow disease progression
Clinical history
- Diagnosed with FL at age 55
- First-line treatment: 6 cycles of BR followed by R maintenance
- –After 4 years of follow-up, disease progression was observed and confirmed by imaging
- Second-line treatment: R2
- –Discontinued due to cytopenias associated with lenalidomide
- Had a durable response; however, night sweats and fatigue indicate the need for third-line treatment
Treatment considerations
- ECOG 0; low comorbidities
- Expressed interest in maintaining active lifestyle and travel schedule
- Lives in a town far away from infusion centers
Would you consider Tazverik
as a treatment option for
this patient?
TAZVERIK® efficacy and safety were evaluated in 2 open-label, independent, single-arm cohorts
(EZH2 WT [n=54] and MT [n=45]) of a multicenter study in patients with histologically confirmed follicular
lymphoma after at least 2 prior systemic therapies. The primary efficacy endpoint was the overall
response rate (ORR) and a secondary efficacy endpoint was duration of response (DOR).1,2
Primary endpoint:
34% ORR*
in WT FL (18/53)
(95% CI: 22%-48%)1,3
Primary endpoint:
69% ORR*
in MT FL (29/42)
(95% CI: 53%-82%)1,3
Median time to overall response for
patients with EZH2 WT FL was
3.9 months (range: 1.6 to 16.3).1
Median time to overall response for patients with EZH2 WT FL was 3.9 months (range: 1.6 to 16.3).1
Median time to overall response for
patients with EZH2 MT FL was
3.7 months (range: 1.6 to 10.9).1
Median time to overall response for patients with EZH2 MT FL was 3.7 months (range: 1.6 to 10.9).1
The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%)1
≤5% of patients experienced
Grade 3 or 4 adverse reactions1
*According to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by Independent Radiology Committee.
BR=bendamustine + rituximab; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; EZH2=enhancer of zeste homolog 2; FL=follicular lymphoma; MT=mutant type; PET=positron emission tomography; R=rituximab; R2=lenalidomide + rituximab; R/R=relapsed or refractory; WT=wild type.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration
of response. Continued approval for these indications may be contingent upon verification and
description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Secondary Malignancies: TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies.
- Embryo-Fetal Toxicity: TAZVERIK can cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception.
The most common (≥20%) adverse reactions in patients with follicular lymphoma are fatigue, upper
respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.
Please see additional Important Safety Information below and full Prescribing Information.
Meet Bruce
Hypothetical patient.
- 72-year-old patient with unknown EZH2 status
- Requires third-line treatment
Current presentation
- Needs active therapy but has history of toxicity
Clinical history
- Diagnosed with FL at age 65, with abnormally enlarged lymph node as well as elevated LDH and beta macroglobulin
- First-line treatment: 4 cycles of BR
- –Did not complete treatment due to severe thrombocytopenia/neutropenia, but still had 3 years of PFS
- Second-line treatment: Was initiated on R2, but discontinued early with the recurrence of severe neutropenia
- –Around 2 years later, patient experiencing weight loss and night sweats
Treatment considerations
- Was recently diagnosed with atrial fibrillation
- Would like to avoid combination therapy
Would you consider Tazverik
as a treatment option for
this patient?
TAZVERIK® efficacy and safety were evaluated in 2 open-label, independent, single-arm cohorts
(EZH2 WT [n=54] and MT [n=45]) of a multicenter study in patients with histologically confirmed follicular
lymphoma after at least 2 prior systemic therapies. The primary efficacy endpoint was the overall
response rate (ORR) and a secondary efficacy endpoint was duration of response (DOR).1,2
Primary endpoint:
34% ORR*
in WT FL (18/53)
(95% CI: 22%-48%)1,3
Primary endpoint:
69% ORR*
in MT FL (29/42)
(95% CI: 53%-82%)1,3
Median time to overall response for
patients with EZH2 WT FL was
3.9 months (range: 1.6 to 16.3).1
Median time to overall response for patients with EZH2 WT FL was 3.9 months (range: 1.6 to 16.3).1
Median time to overall response for
patients with EZH2 MT FL was
3.7 months (range: 1.6 to 10.9).1
Median time to overall response for patients with EZH2 MT FL was 3.7 months (range: 1.6 to 10.9).1
8% of patients
permanently discontinued
treatment and 28% required
dose interruptions due to an
adverse reaction1
8% of patients permanently discontinued treatment and 28% required dose interruptions due to an adverse reaction1
The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%)1
*According to the International Working Group Non-Hodgkin Lymphoma (IWG-NHL) criteria as assessed by Independent Radiology Committee.
BR=bendamustine + rituximab; CI=confidence interval; EZH2=enhancer of zeste homolog 2; FL=follicular lymphoma; LDH=lactate dehydrogenase; MT=mutant type; PFS=progression-free survival; R2=lenalidomide + rituximab; R/R=relapsed or refractory; WT=wild type.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration
of response. Continued approval for these indications may be contingent upon verification and
description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Secondary Malignancies: TAZVERIK increases the risk of developing secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia. Monitor patients long-term for the development of secondary malignancies.
- Embryo-Fetal Toxicity: TAZVERIK can cause fetal harm. Advise patients of potential risk to a fetus and to use effective non-hormonal contraception.
The most common (≥20%) adverse reactions in patients with follicular lymphoma are fatigue, upper
respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.
Please see additional Important Safety Information below and full Prescribing Information.
References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., August 2024. 2. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433-1442. doi:10.1016/S1470-2045(20)30441-1. 3. Data on file.
Meet David, Michael, and Mary – real patients treated with TAZVERIK®
These patient profiles are based on actual patient experiences when treated with TAZVERIK® in a single practice. Certain patient and medical details and identifying information have been omitted and the physician who contributed these profiles was compensated for their time. These profiles are presented only as an example and are not intended to instruct any healthcare provider in the treatment of any illness, nor are they meant to substitute for medical training or to be relied upon in treating any individual patient. Patient experience may vary, and the information presented herein does not encompass all considerations for TAZVERIK® eligibility. The healthcare provider reading this case study should use his or her own knowledge, education, training, and judgment when treating patients.
All patient photos are actor portrayals.
Meet David
- 63 years old, EZH2 MT status
- History of morbid obesity
Presentation
Patient presented with suspected GI bleeding post-gastric bypass
Testing
CT imaging
Biopsy
Findings
Bulky retroperitoneal
lymph nodes
Diagnosis: FL Grade 3A
Next steps
Began treatment for FL
First-line therapy
R-CHOP
6 cycles
Maintenance: Rituximab
Outcome: Complete remission
Follow-up:
18-month PET scan:
- Progressive disease
- New left inguinal adenopathy and T4 paraspinal mass
- FDG-avid with SUV 7.8
Inguinal lymph node biopsy:
- FL Grade 1-2
Second-line therapy
Radiation therapy on the paraspinal mass, followed by lenalidomide + rituximab
Outcome: Complete remission
Follow-up:
At 13-months, presented with lower left extremity pain
PET scan:
- Bulky, FDG-avid pelvic adenopathy
- Highest SUV <10
- FDG-avid adenopathy above and below the diaphragm
Lymph node biopsy:
FL without evidence of transformation to aggressive lymphoma
Third-line therapy
Testing:
EZH2 MT
TAZVERIK
Follow-up:
18-month checkup: No progression, patient remained on treatment
CT=computed tomography; EZH2=enhancer of zeste homolog 2; FDG=18F-fluorodeoxyglucose; FL=follicular lymphoma; GI=gastrointestinal; MT=mutant type; PET=positron emission tomography; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone; SUV=standardized uptake value.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Drug Interactions
Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of strong or moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.
Avoid coadministration of moderate or strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.
Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.
Please see additional Important Safety Information below and full Prescribing Information.
Meet Michael
- 55 years old, EZH2 WT status
- No significant past medical history
Presentation
Patient presented to the emergency room with chest pain, shortness of breath
Testing
Ultrasound of lower
extremities
CT chest scan
with angiography
Biopsy of left groin
lymph node
Findings
Bilateral extensive
DVTs in legs
reaching up to
his iliac veins
Bilateral
pulmonary
embolism
Bulky
lymphadenopathy
above and below
the diaphragm
Diagnosis:
low-grade FL
(WHO Grade 1-2)
Next steps
No known risk factor for coagulable state:
- Thrombectomy procedure
- Anticoagulation medication
Began treatment for FL
First-line therapy
Bendamustine-rituximab
chemoimmunotherapy
6 cycles
PET scan: PR with residual adenopathy
- SUV 8
- Deauville score 4
Maintenance:
Rituximab
Outcome: Partial response
Follow-up:
12-month PET scan:
Progression
Deemed high risk for
recurrence
Repeat lymph node biopsy:
- Low-grade FL
- No evidence of
transformation to
aggressive lymphoma
Second-line therapy
Obinutuzumab/
lenalidomide
10 cycles
PET scan: PR
Complications:
Diarrhea, Grade 3 neutropenia requiring dose interruption then dose reduction to lenalidomide 10 mg
Outcome:
Partial response
Follow up:
Patient developed
progressive
adenopathy after
10 cycles of
second-line therapy
Third-line therapy
Testing:
EZH2 WT
TAZVERIK
12-month imaging:
Patient showed disease
progression
The HCP made a medical decision based on the patient context – some details of which may not be included here – that the patient had no satisfactory alternative treatment options. Prior to using Tazverik, HCPs should apply their independent clinical judgment to an individual patient circumstance when making this determination.
Fourth-line therapy
CAR-T therapy
Follow-up:
No response
CAR-T therapy is a more invasive therapy that, based on their medical judgment at the time, the HCP did not deem appropriate for use as third-line therapy. The patient’s personal situation changed post-treatment with TAZVERIK, making them a candidate for CAR-T in fourth line.
Fifth-line therapy
Bi-specific antibody
clinical trial
Follow-up:
Refractory disease after 3 cycles
Repeat lymph node biopsy:
- Low-grade FL
- No evidence of transformation to aggressive lymphoma
Sixth-line therapy
R-CHOP
consolidated with allogeneic stem cell transplant
Outcome:
Complete response. At last follow-up, patient remained in remission.
CAR-T=chimeric antigen receptor T-cell; CT=computed tomography; DVT=deep vein thrombosis; EZH2=enhancer of zeste homolog 2; FL=follicular lymphoma; PET=positron emission tomography; PR=partial remission; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone; SUV=standardized uptake value; WHO=World Health Organization; WT=wild type.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions
In 99 clinical study patients with relapsed or refractory follicular lymphoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥2% were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia. The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%).
Please see additional Important Safety Information below and full Prescribing Information.
Meet Mary
- 83 years old,* EZH2 WT status
- Medical history includes coronary artery disease post stent placements, cerebrovascular stroke without residual motor or sensory deficits, diabetes, and CKD
Presentation
Patient presented for management of relapsed low-grade FL
with right inguinal mass and lower right extremity edema
Testing
PET scan
Biopsy of pelvic lymph node
Findings
FDG-avid adenopathy in the inguinal,
pelvic retroperitoneal, and bilateral
axial areas
Maximum SUV 9 in the pelvic areas
Diagnosis: FL Grade 1-2
Next steps
Began treatment for FL
First-line therapy
Mini R-CHOP
Outcome:
Complete remission
Follow-up:
At 36-months, patient presented with relapsed disease with right lower extremity edema
PET scan: FDG-avid adenopathy in the inguinal and pelvic regions
Second-line therapy
Radiation therapy
Outcome:
Complete remission
Follow-up:
12-month imaging: Recurrent adenopathy in the axillary and retroperitoneal regions
The patient remained on active surveillance and then developed recurrent left pelvic adenopathy
Repeat lymph node biopsy:
- FL Grade 1-2
- No evidence of transformation to aggressive lymphoma
Third-line therapy
Testing:
EZH2 WT
TAZVERIK
Outcome:
Partial remission
Follow-up:
14-month imaging: Recurrent FDG-avid adenopathy, SUV 17
The HCP made a medical decision based on the patient context – some details of which may not be included here – that the patient had no satisfactory alternative treatment options. Prior to using Tazverik, HCPs should apply their independent clinical judgment to an individual patient circumstance when making this determination.
Fourth-line therapy
Lymph node biopsy:
Transformation to diffuse large B-cell lymphoma.
Anti-CD19 mAb
Outcome:
Partial response
Follow-up:
At Month 4, patient relapsed and was transferred to hospice care.
Anti-CD19 mAb therapy is not approved in FL. Since the patient transformed to DLBCL post-Tazverik treatment, anti-CD19 mAb became the next appropriate option for the patient.
CKD=chronic kidney disease; DLBCL=diffuse large B cell lymphoma; EZH2=enhancer of zeste homolog 2; FDG=18F-fluorodexeoxyglucose; FL=follicular lymphoma; mAB=monoclonal antibody; PET=positron emission tomography; PR=partial remission; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone; SUV=standardized uptake value; WT=wild type.
INDICATIONS
TAZVERIK is indicated for the treatment of:
- Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA approved test and who have received at least 2 prior systemic therapies.
- Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
*Limitation: Clinical studies of tazemetostat did not include sufficient numbers of patients with epithelioid sarcoma or relapsed or refractory follicular lymphoma aged ≥65 years to determine whether they respond differently from younger subjects.1
Please see additional Important Safety Information below and full Prescribing Information.
Reference: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., August 2024.